-50%

est. 2Y upside i

Rank

#4197

Sector

Information Technology

Est. Liquidity

~3Y

Data Quality

Data: High

Veradigm presents a high-risk equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (8%)+50%

Veradigm successfully resolves all outstanding financial reporting issues, achieves relisting on a major exchange, and the ScienceIO acquisition drives significant new revenue in the high-growth healthcare data & analytics segment, leading to a valuation of approximately $732 million.

Base (52%)-10%

Veradigm becomes current with SEC filings and resolves its audit, but revenue remains flat or slightly declines due to intense competition from dominant incumbents like Epic and Oracle Health. The company maintains profitability but struggles to reignite growth, leading to a valuation of approximately $439 million.

Bear (40%)-50%

Despite the SEC investigation closure, Veradigm continues to face challenges with revenue decline and market share erosion from larger competitors. The inability to achieve significant growth or relist on a major exchange, coupled with the severe preference stack, results in an acquisition at a significantly lower valuation of approximately $244 million, wiping out a substantial portion of common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Veradigm has raised a total of $175 million across 2 funding rounds. With a current valuation of approximately $488 million, this represents a funding intensity of approximately 35.8%, indicating a severe preference stack where preferred shareholders hold substantial liquidation preferences ahead of common stock. In an exit at or below the current valuation, common stock holders may receive little to no return.

Dilution Risk

high

Given the company's delisted status and need to potentially fund future growth or operational improvements, there is a high risk of future private funding rounds that could dilute existing common shareholders.

Secondary Liquidity

none

As a delisted company, there is no active public secondary market for Veradigm's stock, and private secondary liquidity is likely very limited.

View all 6 open roles at Allscripts →

Last updated: February 18, 2026

Questions to Ask at the Interview

Strategic questions based on Allscripts's data — designed to show you've done your homework.

  • 1

    “Given the forecast for declining revenue, how does Veradigm plan to differentiate its data and analytics offerings to compete effectively against dominant incumbents like Epic and Oracle Health?”

  • 2

    “What is the detailed roadmap and timeline for becoming current with SEC filings and successfully relisting on a major exchange, and what are the key dependencies for this process?”

  • 3

    “With a significant portion of prior funding potentially holding liquidation preferences, how does Veradigm plan to ensure meaningful returns for common stock holders in a future liquidity event, especially given the current valuation?”

Community

Valuation Sentiment

Our model estimates -50% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.